One of the major challenges in Glioblastoma (GBM) therapy relates with the existence of glioma stem-like cells (GSCs), known to be chemo- and radio-resistant. In our work, nucleolin overexpression in GBM cells resulted in a higher association of liposomes targeting nucleolin. Moreover, nucleolin was suggested as a potential marker in GSCs, and in the corresponding non-stem GBM cells. Doxorubicin delivered by liposomes targeting nucleolin enabled a higher level of cytotoxicity.
